Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envolizumab + lenvatinib + capecitabine after surgery for high-risk biliary tract cancer
ChiCTR2300074241Phase 3Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of envafolimab, lenvatinib and capecitabine in biliary cancer, sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Overall survival and Recurrence-free survival. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
envafolimablenvatinibcapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2300074241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074241.